Product image of Megefren (Megestrol Acetate) supplied by GNH India

Megefren

Active Ingredient:
Megestrol Acetate
Origin:
EU

Megefren (Megestrol Acetate)

Megestrol acetate, the active ingredient in Megefren, is a synthetic progestin presented as an oral formulation for systemic use. It is employed as an appetite stimulant and hormone therapy in certain cancers and in severe weight‑loss conditions such as cancer‑related or AIDS‑related cachexia.

GNH India supplies Megefren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Teva B.V

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Megestrol acetate is used in several oncologic and metabolic conditions where hormone modulation or appetite stimulation is required.

  • Cachexia associated with cancer or AIDS: helps increase appetite and promote weight gain.
  • Advanced breast cancer: provides antineoplastic activity by antagonizing estrogen‑driven tumor growth.
  • Endometrial cancer: used as hormonal therapy to inhibit tumor progression.

How It Works

  • Megestrol acetate acts as an agonist at progesterone receptors, producing progestogenic effects that modulate endocrine pathways. Its glucocorticoid‑like activity contributes to appetite stimulation and may exert antineoplastic effects by influencing cell proliferation and apoptosis in hormone‑sensitive tumors.

Side Effects

Megestrol acetate may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Weight gain: increased appetite leading to excess caloric intake.
  • Edema: peripheral fluid accumulation, often mild.
  • Fatigue: generalized tiredness without exertion.
  • Hot flashes: transient vasomotor symptoms.
  • Increased appetite: heightened desire for food.

Serious or Rare Side Effects

  • Thromboembolic events: deep‑vein thrombosis or pulmonary embolism.
  • Adrenal suppression: reduced endogenous cortisol production.
  • Severe allergic reaction: rash, swelling, or anaphylaxis.
  • Hyperglycemia: elevated blood glucose levels, especially in diabetics.
  • Cushingoid features: facial rounding, central obesity, and skin changes.

Precautions & Warnings

When prescribing Megestrol acetate, clinicians should consider several safety measures.

  • Monitor blood glucose: hyperglycemia may develop, especially in diabetic patients.
  • Assess thromboembolic risk: evaluate history of clotting disorders before initiation.
  • Evaluate adrenal function: prolonged use can suppress endogenous cortisol.
  • Use caution in cardiovascular disease: fluid retention may exacerbate heart failure.
  • Avoid in known hypersensitivity: discontinue if allergic reactions occur.
  • Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Megestrol acetate can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce therapeutic levels.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase exposure and risk of toxicity.
  • Anticoagulants (e.g., warfarin): may enhance anticoagulant effect, increasing bleeding risk.

Moderate Interactions (Monitor Closely)

  • Antidiabetic agents: may require dose adjustment due to altered glucose control.
  • Antihypertensives: fluid retention can blunt blood‑pressure‑lowering effects.
  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): combined use may increase gastrointestinal irritation.

Frequently Asked Questions

Megefren, containing megesterol acetate, is prescribed for appetite stimulation in patients with cancer‑related or AIDS‑related cachexia, and as hormone therapy for advanced breast cancer and endometrial cancer. These indications reflect its progestogenic and glucocorticoid‑like activities.

Megesterol acetate binds to progesterone receptors, producing progestogenic effects that influence hormone‑dependent pathways. Its glucocorticoid‑like activity also stimulates appetite and may interfere with tumor cell proliferation, providing both metabolic and antineoplastic benefits.

The specific dose of Megefren is determined by the prescribing clinician based on the patient’s condition, severity, and response. Dosage regimens are individualized and should follow the prescriber’s instructions and local clinical guidelines.

Safety of megesterol acetate in pregnancy or lactation has not been fully established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Megefren, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other appetite stimulants such as dronabinol or mirtazapine, megesterol acetate offers both progestogenic and glucocorticoid‑like actions, which can provide stronger appetite stimulation and additional antineoplastic effects. However, its side‑effect profile, including potential for thromboembolic events, differs and must be considered.

Megefren should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain its stability and potency.

Megefren is taken orally, usually as a tablet or capsule, with or without food as directed by the prescriber. The exact administration instructions, including timing and any required food considerations, should follow the healthcare professional’s guidance.

Serious risks include thromboembolic events such as deep‑vein thrombosis, adrenal suppression leading to cortisol deficiency, severe allergic reactions, and significant hyperglycemia. Patients should be monitored closely for these complications, especially during prolonged therapy.

Megefren should be avoided in individuals with known hypersensitivity to megesterol acetate or any excipients, in patients with active uncontrolled thromboembolic disease, and in those with severe adrenal insufficiency unless under specialist supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.